Ketanserin
| R-41468, R41468, R-41,468, KJK-945, R-49945, R49945 | |
|---|---|
| Salts [] | |
|---|---|
| Ketanserin tartrate | |
| Molecular structure drawn from PubChem coordinates |
| Rotamer [] | |
|---|---|
| Conformer structure via 3Dmol.js |
| Physical properties [] | |
|---|---|
| Molecular mass | 395.40 g/mol [1] |
| Predicted LogP | 2.6 [1] |
| Structural Identifiers [] | |
|---|---|
| Molecular formula | C22H22FN3O3 |
| IUPAC name | 3-[2-[4-(4-fluorobenzoyl)piperidin-1-yl]ethyl]-1H-quinazoline-2,4-dione |
| SMILES | C1CN(CCC1C(=O)C2=CC=C(C=C2)F)CCN3C(=O)C4=CC=CC=C4NC3=O |
| InChI | InChI=1S/C22H22FN3O3/c23-17-7-5-15(6-8-17)20(27)16-9-11-25(12-10-16)13-14-26-21(28)18-3-1-2-4-19(18)24-22(26)29/h1-8,16H,9-14H2,(H,24,29) |
| InChIKey | FPCCSQOGAWCVBH-UHFFFAOYSA-N |
| CAS number | 74050-98-9 |
| UNII | 97F9DE4CT4 |
| PubChem CID | 3822 |
| Pharmacokinetics[] | |
|---|---|
| Onset | Time to peak levels: 0.53–2.3 hours (range 0.25–5.0 hours)[3] |
| Elimination half-life | 3.5–29 hours[4][5] |
| Metabolism | Extensive |
| Excretion | Urine; 2% unchanged |
| Routes of administration | Oral |
Ketanserin (also known as Ketanserine, Ketanserinum, Ketanserina, Ketaserin, 3-(2-(4-(4-Fluorobenzoyl)piperidin-1-yl)ethyl)quinazoline-2,4(1H,3H)-dione, Serefrex, R 41468, R 41,468, 3-(2-(4-(4-Fluorobenzoyl)piperidinol)ethyl)-2,4(1H,3H)-quinazolinedione or 2,4(1H,3H)-Quinazolinedione, 3-(2-(4-(4-fluorobenzoyl)-1-piperidinyl)ethyl)-) is a substance of the benzylamine class.
Chemistry
Salts []
Ketanserin is typically found in the form of its tartrate salt.
Stereochemistry []
Ketanserin is achiral.
Druglikeness
Lipinski's rule of five
Ketanserin matches Lipinski's rule of five.Pharmacology
ATC Classification
- cardiovascular system (C)
- antihypertensives (C02)
- other antihypertensives (C02K)
- serotonin antagonists (C02KD)
- ketanserin (C02KD01)
MeSH Classification
- antihypertensive agents (M0001456)
- platelet aggregation inhibitors (M0017012)
- serotonin antagonists (M0019685)
Interactions []
Subjective effects []
| emily / Ketanserin [] | |
|---|---|
Routes:
| |
| Pilz / Ketanserin [] | |
|---|---|
Routes:
| |
Legal status []
- Other: Ketanserin is a Rx-only.
See also []
External links []
References []
National Center for Biotechnology Information. PubChem Compound Summary for CID 3822, Ketanserin. Accessed November 20, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/3822
U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Ketanserin. UNII: 97F9DE4CT4. Global Substance Registration System. Accessed November 20, 2026. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/97F9DE4CT4
Heykants J, Van Peer A, Woestenborghs R, Gould S, Mills J. Pharmacokinetics of ketanserin and its metabolite ketanserin-ol in man after intravenous, intramuscular and oral administration. Eur J Clin Pharmacol. 1986; 31(3):343–350. PMID 3792432.
Cold GE, Dahl BL. Topics in Neuroanaesthesia and Neurointensive Care: Experimental and Clinical Studies upon Cerebral Circulation, Metabolism and Intracranial Pressure. Springer Science & Business Media. 11 November 2013. https://books.google.com/books?id=cYnqCAAAQBAJ&pg=PA193
Antihypertensive Drugs Today. VSP. 1992. https://books.google.com/books?id=PghVgVDfF7UC&pg=PA191
Data sources []
| Source | Status | Updated (UTC) |
|---|---|---|
| dosing | missing (no dosing statistics) | 2026-11-20 03:05:24 |
| drugspro | missing (no DrugsPRO reagent data) | 2026-11-20 03:05:20 |
| erowid | missing (no Erowid substance of that name) | 2026-11-20 03:05:20 |
| gsrs | ok | 2026-11-20 03:05:21 |
| hmdb | missing (hmdb.ca refused automated access to HMDB0253783) | 2026-11-20 03:05:20 |
| kegg | ok | 2026-11-20 03:05:22 |
| pubchem | ok | 2026-11-20 03:05:20 |
| missing (no r/tripreports posts mention it) | 2026-11-20 03:05:20 | |
| sider | missing (not in SIDER) | 2026-11-20 03:05:20 |
| structure | ok | 2026-11-20 03:05:20 |
| wikipedia | ok | 2026-11-20 03:05:21 |